HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥SKB500 (a Novel B7-H3–Targeted Antibody-Drug Conjugate) in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Results From a Phase I Study 🎙️Dr. Haifeng Liu 🔢3816RO 🎯ORR 67.2%, Median DoR 5.8mo, Median PFS 7.2mo (n=61) 🎯12mg/kg Q3W Better Tolerated (Grade≥3 TRAEs 47.5% vs 61.9%) With Better Activity Than 16mg/kg ☑️NCT06736327 🔗 https://t.co/a1n3LKVbtq @OncoAlert @Larvol @myESMO @IASLC
热度 6 · 5 赞 · 0 回复 · 1 转发
会议摘要
NCT06736327NCT06736327按 - **标题 / Title：** A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors 对上
- **标题 / Title：** A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors读摘要原文 →来源：HHorinouchi · x.com